FDA Cracks Down Hard — 30 Telehealth Companies Warned Over Compounded Ozempic & Zepbound Copies
The FDA sent warning letters to 30 telehealth companies for false claims about compounded GLP-1 drugs like semaglutide and tirzepatide.
/ 74 items
#NVO↓
Novo Nordisk Slashes Wegovy & Ozempic List Prices by Up to 50% — But Analysts Say It Won’t Dent Lilly’s Lead
Novo Nordisk slashes list prices for Wegovy, Ozempic & Rybelsus to $675/month starting Jan 2027—50% cut for Wegovy. Helps high-deductible plans, but BofA sees little threat to Eli Lilly’s GLP-1 lead.
CagriSema Falls Short vs Zepbound in Head-to-Head Trial
Novo’s new obesity shot CagriSema lost a head-to-head battle with Lilly’s tirzepatide. 23% weight loss is strong but not enough to win this round.
Novo Nordisk Sues Hims & Hers Over Weight-Loss Drug Knockoffs
Danish pharma giant Novo Nordisk files patent lawsuit against telehealth company Hims & Hers for selling unauthorized versions of Wegovy and Ozempic weight-loss medications.
Hims Pulls Copycat Wegovy Weight-Loss Pill After Federal Pressure
Hims & Hers Health stops selling its cheaper Wegovy copycat pill just two days after launch following FDA crackdown and Justice Department investigation into compounded weight-loss drugs.
FDA Cracks Down on Compounded GLP-1 Weight Loss Drugs
FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.